Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 2, 2020Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)
SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...
-
Jun 1, 2020
Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...
-
May 27, 2020Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.
WALTHAM, Mass. and KING OF PRUSSIA, Penn. 27 May 2020 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited...
-
May 26, 2020“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
Redmond, Wash., USA, and New York 26 May 2020 A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic...
-
May 18, 2020
ST GALLEN, CH and MOUNTAIN VIEW, Calif., 18 May, 2020 – Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six...
-
May 14, 2020
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Jacques Theurillat as new Chairman of the Board of Directors Etienne Jornod appointed...
-
May 7, 2020- Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach
Osaka, JAPAN, and King of Prussia, PA, USA – 7 May 2020 – The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a...
-
May 6, 2020
Plasma-derived therapeutic with potential to treat serious complications of COVID-19. MELBOURNE, AUSTRALIA – CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will...
-
Apr 21, 2020
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02)...
-
Apr 21, 2020Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method
PHILADELPHIA, PA – April 21, 2020 – Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than currently approved...
-
Apr 8, 2020COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer
King of Prussia, Pa. and Sioux Falls, S.D. 08 Apr 2020 Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced today their...
-
Apr 6, 2020Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Osaka, JAPAN, and King of Prussia, PA, USA 06 Apr 2020 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company...
-
Apr 6, 2020
GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY −Partnership brings together world-leading plasma companies to focus on developing and...
-
Apr 3, 2020
Safeguarding our people and communities remains our top priority. 03 Apr 2020 As the COVID-19 pandemic evolves, we are continuing to take steps to ensure the health and safety of our workforce and...
-
Mar 31, 2020
AGM will take place as planned on 14 May, 2020 under extraordinary conditions Shareholders are not allowed to attend in person and are requested to vote via independent proxy St Gallen, 31 March...
-
Mar 31, 2020
This news release is intended for medical and pharmaceutical trade media and financial media only 31 Mar 2020 Seqirus, a global leader in influenza prevention, today announced that its adjuvanted...
-
Mar 23, 2020
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. By Anthony Farina – Chief Communications Officer, CSL Limited | 23 Mar 2020...
-
Mar 18, 2020
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. Anthony Farina – Chief Communications Officer, CSL Limited 18 Mar 2020 As...
-
Mar 12, 2020
Net sales and EBITDA exceeded raised full-year guidance as a result of continued execution of the three strategic growth drivers Etienne Jornod to step down as Executive Chairman. Jacques...
-
Mar 3, 2020
St Gallen, 3 March 2020 - Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This...
-
Feb 20, 2020
Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China Gives Vifor Pharma access to largest iron...
-
Feb 17, 2020
St Gallen, 17 February 2020 – Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). A PRV entitles the holder to...
-
Feb 13, 2020Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative
Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative 13 Feb 2020 PHILADELPHIA – February 13, 2020 – Researchers at the...
-
Feb 12, 2020
CSL Limited's statement on Coronavirus Coronavirus is quite different to influenza virus so it is not a core area of focus for CSL or Seqirus. However, we have investigated possible adjacencies in...
-
Feb 11, 2020CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
KING OF PRUSSIA, Pa.– February 11, 2020 – Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin...